Table 1 Characteristics of the study population
Overall population N = 158 | Patients with KTD n = 42 | Patients without KTDn = 116 | p* | ||||
|---|---|---|---|---|---|---|---|
Female (%) | 34 | 21.5% | 8 | 19.0% | 26 | 22.4% | 0.649 |
Age [yrs] median (IQR) | 42 | 35–48 | 42 | 37–45 | 42 | 34–49 | 0.591 |
Non-Caucasian (%) | 5 | 3.2% | 2 | 4.8% | 3 | 2.6% | 0.490 |
BMI (Kg/m2) median (IQR) | 22,9 | 20,3–25,2 | 23,5 | 20,7–25,4 | 22,5 | 20,2–25,2 | 0.339 |
TDF as part of first ARV regimen (%) | 83 | 52,5% | 14 | 33,3% | 69 | 59,5% | 0.004 |
Previous therapy duration [yrs] median (IQR) | 0.0 | 0.0–6.1 | 0.6 | 0.0–8.2 | 0.0 | 0.0–3.8 | 0.034 |
TDF duration (months) median (IQR) | 66 | 24–101 | 76 | 30–110 | 59 | 23–95 | 0.090 |
Use of protease inhibitors (%) | 103 | 65.2% | 26 | 61.9% | 77 | 66.4% | 0.602 |
CD4+ (cells/μL) median (IQR) | 373 | 228–599 | 430 | 251–635 | 371 | 224–580 | 0.638 |
HIV-RNA (log cps/mL) median (IQR) | 3.8 | 0.0–5.0 | 0.0 | 0.0–4.5 | 4.0 | 0.0–5.0 | 0.012 |
Creatinine (mg/dL) median (IQR) | 0.84 | 0.72–0.94 | 0.84 | 0.70–0.99 | 0.83 | 0.73–0.92 | 0.534 |
GFR (MDRD equation) median (IQR) | 103 | 89–117 | 106 | 89–118 | 101 | 89–117 | 0.586 |
HCV coinfection (%) | 18 | 11.4% | 6 | 14.3% | 12 | 10.3% | 0.491 |
Diabetes (%) | 11 | 7.0% | 5 | 11.9% | 6 | 5.2% | 0.142 |
Hypertension (%) | 20 | 12.7% | 8 | 19.0% | 12 | 10.3% | 0.146 |
Bone diseasea (%) | 55 | 34.8% | 23 | 54.8% | 32 | 27.6% | 0.002 |